NCT07273825 is a NA clinical trial of Geranium Aromatherapy in Aromatherapy (Geranium Essential Oil), sponsored by Universitas Muhammadiyah Surakarta.

Who is sponsoring NCT07273825?

NCT07273825 is sponsored by Universitas Muhammadiyah Surakarta.

What drugs are being tested in NCT07273825?

Interventions in NCT07273825: Placebo Aromatherapy (Non-Geranium Neutral Oil), Geranium Aromatherapy.

What condition does NCT07273825 study?

NCT07273825 studies Aromatherapy (Geranium Essential Oil), Chronic Kidney Disease on Hemodialysis, End Stage Renal Disease (ESRD), Fatigue, Poor Sleep Quality, Aromatherapy.

Is NCT07273825 still recruiting?

NCT07273825 is currently completed. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT07273825

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Geranium Essential Oil Aromatherapy on Fatigue and Sleep Quality in Patients Undergoing Hemodialysis

Completed NA Last updated 10 December 2025

What this trial tests

NA trial testing Placebo Aromatherapy (Non-Geranium Neutral Oil) in Aromatherapy (Geranium Essential Oil) in 90 participants. Completed in 30 September 2025.

Timeline

1 January 2025

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	Universitas Muhammadiyah Surakarta
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 January 2025
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across Indonesia

Drugs / interventions tested

Placebo Aromatherapy (Non-Geranium Neutral Oil)
Geranium Aromatherapy

Conditions studied

Aromatherapy (Geranium Essential Oil) — all drugs for Aromatherapy (Geranium Essential Oil) →
Chronic Kidney Disease on Hemodialysis — all drugs for Chronic Kidney Disease on Hemodialysis →
End Stage Renal Disease (ESRD) — all drugs for End Stage Renal Disease (ESRD) →
Fatigue — all drugs for Fatigue →

Sponsor

Universitas Muhammadiyah Surakarta

Who can join

Adults 18 to 65, any sex, with Aromatherapy (Geranium Essential Oil) or Chronic Kidney Disease on Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemodialysis is a life-sustaining therapy for individuals with chronic kidney disease; however, it is often accompanied by adverse effects such as fatigue and poor sleep quality. Fatigue is one of the most frequently reported symptoms among hemodialysis patients and can significantly impair daily functioning, psychosocial wellbeing, and overall quality of life. Sleep disturbances are also common and may further exacerbate physical and emotional stress. Aromatherapy using essential oils has been explored as a non-pharmacological intervention to reduce fatigue and improve sleep quality. Geranium essential oil contains active compounds such as geraniol, citronellol, and terpineol, which possess relaxing, anti-inflammatory, and analgesic properties. These characteristics indicate its potential to alleviate fatigue and promote better sleep. This study aims to evaluate the effect of geranium essential oil aromatherapy on fatigue and sleep quality in patients undergoing hemodialysis. The study employs a randomized cross-over design involving 90 participants who meet predetermined inclusion criteria. Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F), and sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI). Assessments will be conducted before and after the intervention period. The findings of this study are expected to provide scientific evidence supporting the use of geranium essential oil aromatherapy as a safe, accessible complementary therapy that may help reduce fatigue and improve sleep quality among hemodialysis patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Universitas Muhammadiyah Surakarta trials

Trials by the same sponsor.

NCT07515677 — Digital Discharge Planning to Improve Self-Management in Patients With Diabetes Mellitus · NA · not yet recruiting
NCT07412548 — Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients · NA · not yet recruiting
NCT07405593 — Head Up Position and Murottal Therapy in Stroke Patients · NA · not yet recruiting
NCT07464418 — Effect of Intradialytic Eating Timing on Hemodynamic Stability and Dialysis Adequacy in Hemodialysis Patients · NA · completed
NCT07302178 — Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07273825 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Muhammadiyah Surakarta
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07273825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing